Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2014

01-02-2014

RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients

Authors: Giuseppe Derosa, Arrigo F. G. Cicero, Anna Carbone, Fabrizio Querci, Elena Fogari, Angela D’Angelo, Pamela Maffioli

Published in: Inflammation | Issue 1/2014

Login to get access

Abstract

This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.
Literature
1.
Grundy, S.M., J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr., J.A. Spertus, F. Costa, American Heart Association, and National Heart, Lung, and Blood Institute. 2005. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17): 2735–2752.PubMedCrossRef
2.
WRITING GROUP MEMBERS, D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, T.B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P.M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M.M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V.L. Roger, W. Rosamond, R. Sacco, P. Sorlie, V.L. Roger, T. Thom, S. Wasserthiel-Smoller, N.D. Wong, J. Wylie-Rosett, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2010. Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation 121(7): e46–e215.
3.
Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, and American Society of Hypertension Writing Group. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(1): 42–50.PubMedCrossRef
4.
Wald, D.S., M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald. 2009. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. American Journal of Medicine 122(3): 290–300.CrossRefPubMed
5.
de la Sierra, A., and M. Volpe. 2013. Olmesartan-based therapies: An effective way to improve blood pressure control and cardiovascular protection. Journal of Hypertension 31(1): S13–S17.PubMedCrossRef
6.
Lichtenstein, A.H., L.J. Appel, M. Brands, M. Carnethon, S. Daniels, H.A. Franch, B. Franklin, P. Kris-Etherton, W.S. Harris, B. Howard, N. Karanja, M. Lefevre, L. Rudel, F. Sacks, L. Van Horn, M. Winston, and J. Wylie-Rosett. 2006. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 2186–2191.PubMedCrossRef
7.
Epstein, B.J., K. Vogel, and B.F. Palmer. 2007. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67(9): 1309–1327.PubMedCrossRef
8.
Oparil, S., and M. Weber. 2009. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy. Postgraduate Medicine 121(2): 25–39.PubMedCrossRef
9.
Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, B.J. Materson, H.R. Black, J.L. Izzo Jr., S. Oparil, and M.A. Weber. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(2): 90–98.PubMedCrossRef
10.
Nesbitt, S.D., A. Shojaee, J.F. Maa, and M.R. Weir. 2013. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). Journal of Human Hypertension 27(7): 445–452.PubMedCrossRef
11.
European Diabetes Policy Group. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16: 716–730.CrossRef
12.
Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260–266.PubMedCrossRef
13.
Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef
14.
Klose, S., and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). Journal of Clinical Chemistry and Clinical Biochemistry 15: 121–130.
15.
Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2nd ed, ed. H.U. Bermeyer, 18–31. New York: Academic.
16.
Havel, R.J., H.A. Edr, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34: 1345–1353.PubMedCentralCrossRefPubMed
17.
Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.PubMedCrossRef
18.
Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941–946.PubMedCrossRef
19.
Rifai, N., R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136–2141.PubMedCrossRef
20.
Hasegawa, M., S. Sato, and K. Takehara. 1999. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clinical and Experimental Immunology 117: 159–165.PubMedPubMedCentralCrossRef
21.
De Fronzo, R.A., J.A. Tobin, and B. Andres. 1979. Glucose clamp technique, a method for quantifying insulin secretion and resistance. American Journal of Physiology 237: 214–223.
22.
Ferrannini, E., G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua. 1987. Insulin resistance in essential hypertension. New England Journal of Medicine 317(6): 350–357.CrossRefPubMed
23.
Winer, B.J. 1971. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill.
24.
Fogari, R., A. Zoppi, A. Mugellini, P. Preti, T. Perrone, P. Maffioli, and G. Derosa. 2012. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opinion on Pharmacotherapy 13(5): 629–636.PubMedCrossRef
25.
Derosa, G., P. Maffioli, S.A. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, I. Palumbo, E. Fogari, A. D’Angelo, and A.F. Cicero. 2010. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertension Research 33(8): 790–795.PubMedCrossRef
26.
Fogari, R., G. Malamani, L. Corradi, A. Mugellini, P. Preti, A. Zoppi, and G. Derosa. 2010. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Advances in Therapy 27(1): 48–55.PubMedCrossRef
27.
Fogari, R., G. Derosa, A. Zoppi, A. Rinaldi, P. Preti, P. Lazzari, and A. Mugellini. 2008. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertension Research 31(1): 43–50.PubMedCrossRef
28.
Fogari, R., G. Derosa, A. Zoppi, P. Lazzari, L. Corradi, P. Preti, and A. Mugellini. 2008. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Internal Medicine 47(5): 361–366.PubMedCrossRef
29.
Fogari, R., A. Zoppi, A. Mugellini, P. Preti, M. Destro, A. Rinaldi, and G. Derosa. 2006. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Advances in Therapy 23(5): 680–695.PubMedCrossRef
30.
Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Preti, and G. Derosa. 2012. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opinion on Pharmacotherapy 13(8): 1091–1099.PubMedCrossRef
31.
Fogari, R., P. Maffioli, A. Mugellini, A. Zoppi, P. Lazzari, and G. Derosa. 2012. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. European Journal of Gastroenterology and Hepatology 24(2): 164–171.PubMedCrossRef
32.
Fogari, R., A. Zoppi, P. Maffioli, P. Lazzari, A. Mugellini, and G. Derosa. 2011. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opinion on Pharmacotherapy 12(16): 2441–2448.PubMedCrossRef
33.
Fogari, R., A. Mugellini, M. Destro, L. Corradi, P. Lazzari, A. Zoppi, P. Preti, and G. Derosa. 2012. Losartan and amlodipine on myocardial structure and function: A prospective, randomized, clinical trial. Diabetic Medicine 29(1): 24–31.PubMedCrossRef
34.
Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Lazzari, C. Monti, and G. Derosa. 2011. Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study. Expert Opinion on Pharmacotherapy 12(9): 1351–1358.PubMedCrossRef
35.
Derosa, G., and P. Maffioli. 2011. Drug safety evaluation of amlodipine. Expert Opinion on Drug Safety 10(5): 795–804.PubMedCrossRef
36.
Chrysant, S.G., M. Melino, S. Karki, J. Lee, and R. Heyrman. 2008. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics 30(4): 587–604.PubMedCrossRef
37.
Jackson, M.B., and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143–152.PubMedCrossRef
38.
Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84–89.PubMedCrossRef
39.
Bouskila, M., U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: A relevant player in PPARgamma–agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(1): S17–S23.CrossRef
40.
Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731–737.PubMedCrossRef
41.
Berg, A.H., T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947–953.PubMedCrossRef
42.
Zwacka, T.P., V. Hornbach, and J. Torzewski. 2001. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 103: 1194–1197.CrossRef
43.
Gerszten, R.E., E.A. Garcia-Zepeda, Y.C. Lim, M. Yoshida, H.A. Ding, M.A. Gimbrone Jr., A.D. Luster, F.W. Luscinskas, and A. Rosenzweig. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398(6729): 718–723.PubMedCrossRef
44.
Charo, I.F., and M.B. Taubman. 2004. Chemokines in the pathogenesis of vascular disease. Circulation Research 95(9): 858–866.PubMedCrossRef
45.
Botti, C., C. Maione, G. Dogliotti, P. Russo, G. Signoriello, A.M. Molinari, M.M. Corsi, V. Sica, and G. Cobellis. 2012. Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. Journal of Biological Regulators and Homeostatic Agents 26(1): 67–79.PubMed
46.
Tanaka, Y., D.H. Adams, S. Hubscher, H. Hirano, U. Siebenlist, and S. Shaw. 1993. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361(6407): 79–82.PubMedCrossRef
47.
Schall, T.J., K. Bacon, R.D. Camp, J.W. Kaspari, and D.V. Goeddel. 1993. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. Journal of Experimental Medicine 177(6): 1821–1826.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients
Authors
Giuseppe Derosa
Arrigo F. G. Cicero
Anna Carbone
Fabrizio Querci
Elena Fogari
Angela D’Angelo
Pamela Maffioli
Publication date
01-02-2014
Publisher
Springer US
Published in
Inflammation / Issue 1/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9724-x

Other articles of this Issue 1/2014

Inflammation 1/2014 Go to the issue

OriginalPaper

Activin A: A Potential Therapeutic Target for Characterizing and Stopping Joint Pain Early in Rheumatoid Arthritis Patients

OriginalPaper

Leukocyte Depletion During CPB: Effects on Inflammation and Lung Function

OriginalPaper

Thymol Inhibits LPS-Stimulated Inflammatory Response via Down-Regulation of NF-κB and MAPK Signaling Pathways in Mouse Mammary Epithelial Cells

OriginalPaper

Serum Analysis of Coagulation Factors in IPF and NSIP

OriginalPaper

Effects of OX40–OX40L Interaction on the Nuclear Factor of Activated T Cells c1 in ApoE-Deficient Mice

OriginalPaper

Baicalin Attenuates Brain Edema in a Rat Model of Intracerebral Hemorrhage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits